Table 2.
Treatment Efficacy in Patients Treated with Sorafenib for Progressive RAI-Refractory DTC
| N (%) | |
|---|---|
| Disease response | |
| CR | 0 |
| PR | 25 (25%) |
| SD ≥6 months | 41 (42%) |
| Disease control ratea | 66 (67%) |
| Disease control durationb | |
| <6 months | 37 (38%) |
| 6–12 months | 24 (25%) |
| 12–18 months | 14 (14%) |
| 18–24 months | 5 (5%) |
| ≥24 months | 18 (18%) |
| Disease control (PR or SD) ≥6 months | 61 (62%) |
Tumor responses were assessed with the use of Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
a
Disease control rate was calculated as CR + PR + SD ≥6 months.
b
Disease control duration was calculated as duration of partial or stable disease.
CR, complete response; PR, partial response; SD, stable disease.